Side-by-side · Research reference

DSIPvsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BHuman-MechanisticDraft12/40 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

DSIP

Thymalin

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Thymalin

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

5–10 mg / day IM × 5–10 daysKhavinson 2002

Frequency

Once daily, pre-sleep

Once daily during cycle

Lower / starter dose

50 mcg pre-sleep

2.5 mg / day

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Russian clinical + in vitroKhavinson 2002

Duration

8–12 weeks per cycle

5–10 day cycles, 1–2× per year

Reconstitution

Bacteriostatic water

Saline or bacteriostatic water

Timing

30–60 min pre-sleep

Morning preferred

Half-life

Short plasma; CNS effects last hours

Hours (estimated)

04Side Effects & Safety

Parameter

DSIP

Thymalin

Injection site reaction

Mild irritation

Mild erythema at IM site

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

Limited Western data

Pregnancy / OB

Avoid

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

DSIP

Thymalin

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Injection site

SQ — abdomen. Rotate sites.

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

30–60 min pre-sleep.

Morning preferred during cycle.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Needle

29–31G insulin syringe.

23–25G, 25–38 mm IM needle.

06Stack Synergy

DSIP

— no documented stacks

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001